Gutenberg Open Science: Identification of responders to immune checkpoint therapy : which biomarkers have the highest value?

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-6278

Full metadata record

DC Field	Value	Language
dc.contributor.author	Liebl, Magdalena C.	-
dc.contributor.author	Hofmann, Thomas G.	-
dc.date.accessioned	2021-08-13T09:50:22Z	-
dc.date.available	2021-08-13T09:50:22Z	-
dc.date.issued	2019	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/6288	-
dc.description.abstract	Evasion of immune recognition by the innate and acquired immune system is a major principle of tumour cells and belongs to the hallmarks of cancer. Immune checkpoint inhibitor-based cancer therapies targeting the co-inhibitory receptors CTLA-4 or PD-1 have received enormous scientific and clinical attention during the last few years, because of promising clinical results observed in the treatment of different cancer entities including melanoma and cutaneous squamous cell carcinoma. However, the enthusiasm about the effects of the immune checkpoint inhibitors is muted as only a subfraction of patients shows a stable clinical response. To predefine the patient cohorts that may benefit from immune checkpoint therapy, rigorous biomarker analyses, which predict the response to these novel therapies, need to be performed. In addition, combination of immune checkpoint therapy with classical DNA-damaging chemotherapy or radiotherapy, which positively affects tumour neo-antigen presentation, appears to be a promising approach in optimizing patients’ response. In this review, we briefly summarize important biomarkers for patient stratification and discuss the current limitations of these biomarkers in defining responders vs. non-responders to immune checkpoint therapy.	en_GB
dc.language.iso	eng	de
dc.rights	CC BY-NC	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Identification of responders to immune checkpoint therapy : which biomarkers have the highest value?	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-6278	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	Journal of the European Academy of Dermatology and Venereology	de
jgu.journal.volume	33	de
jgu.journal.issue	S8	de
jgu.pages.start	52	de
jgu.pages.end	56	de
jgu.publisher.year	2019	-
jgu.publisher.uri	https://doi.org/10.1111/jdv.15992	de
jgu.publisher.issn	1468-3083	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1111/jdv.15992
jgu.organisation.ror	https://ror.org/023b0x485
Appears in collections:	JGU-Publikationen

Files in This Item:

	File	Description	Size	Format
	liebl_magdalena_c.-identification-20210813114712848.pdf		172.38 kB	Adobe PDF	View/Open

Show simple item record